With great leaps in innovation and scientific discovery in recent years, the highly regulated, fast-paced pharma/biotech industry finds itself at a critical juncture. The integration of cutting-edge technologies such as AI/ML, new R&D data platforms, and robotics into R&D processes has shifted from optional to essential for maintaining competitiveness and driving progress.
This technological transition in biopharma R&D is not without its challenges. Organizations must navigate many considerations, from the complexities of creating interoperable data ecosystems to the necessity of fostering a culture of innovation and adaptability.
This comprehensive webinar offers a deep dive into the current state of tech adoption in biopharma, highlighting both the opportunities and obstacles that lie ahead. It's designed for lab managers, researchers, and IT professionals seeking to understand how technology can transform their work and the broader industry landscape.
Our expert panelists, leaders from Eli Lilly and Benchling, share real-world insights on harnessing technology to streamline workflows, enhance collaboration, and ultimately, accelerate the journey from bench to market. They delve into the practicalities of adopting new technologies, the importance of data harmonization, and strategies for overcoming resistance to change within established research environments.
Download this insightful webinar to learn more about:
- Strategies for integrating emerging technologies into biopharma R&D processes to enhance efficiency and innovation
- The importance of FAIR (findability, accessibility, interoperability, and reusability) data principles and the challenges in achieving interoperability and reusability of data
- How to overcome adoption barriers, including insights on the complexities of change management and technology implementation in a highly regulated environment
- Real-world applications and benefits of tech adoption from industry leaders
- The future of biopharma R&D, focusing on the evolving role of R&D data platforms, AI/ML tools, and automation in shaping next-generation pharmaceuticals
Discover how your organization can embrace the tech transformation to thrive in the rapidly evolving biopharma industry.
Panelists
DeAnna Zacherl
Executive director, technology for BIOTDR, Genetic Medicines, Neuroscience & Pain, Eli Lilly
Malay Gandhi
Chief strategy officer, Benchling